Abstract
During the last CMR meeting in Naantali, Finland, we presented how the research in our laboratories in collaboration with the Institut ftir Diagnostikforschung, Berlin, Germany, has dramatically converted metalloporphyrins from being used as tumor-seeking agents to markers of myocardial infarction (MI) (1). This represents a three-episode story. We started with an investigation in primary and secondary liver tumors and found that the observed specific enhancement could be attributed only to nonviable instead of viable tumoral components (2). A subsequent study on several porphyrin agents in induced benign necrosis supported the finding in tumors (3). Eventually, we ended up with a novel application for metalloporphyrinenhanced MRI to visualize acute myocardial infarction (46). Since intravenous injection of metalloporphyrins has already been demonstrated to be effective for accurate identification and localization of irreversible myocardial infarcts in rats (4,5) and dogs (6), the current study was designed to deliver the porphyrin agent into the coronary artery with only 1/10th of the intravenous dose in order to assess (a) whether the necrotic myocardium can be accurately labeled by virtually a single pass of the agent through reperfused coronary artery and (b) whether this technique can be combined with percutaneous transluminal coronary angioplasty (PTCA) to function as an in vivo
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
